Victory Capital Management Inc. Has $310,000 Stock Position in Certara, Inc. (NASDAQ:CERT)

Victory Capital Management Inc. lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 32.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,347 shares of the company’s stock after selling 10,942 shares during the quarter. Victory Capital Management Inc.’s holdings in Certara were worth $310,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CERT. Mubadala Investment Co PJSC bought a new position in shares of Certara in the fourth quarter worth about $169,135,000. Wasatch Advisors LP boosted its position in Certara by 23.4% during the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after acquiring an additional 932,598 shares during the last quarter. Norges Bank bought a new stake in shares of Certara during the 4th quarter valued at about $14,262,000. Geneva Capital Management LLC grew its position in shares of Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after buying an additional 579,349 shares during the period. Finally, Edmond DE Rothschild Holding S.A. increased its stake in Certara by 93.1% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock valued at $13,532,000 after purchasing an additional 370,820 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Robert W. Baird reduced their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Barclays dropped their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. KeyCorp reduced their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, UBS Group reduced their target price on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $17.79.

Certara Stock Performance

CERT opened at $10.86 on Tuesday. Certara, Inc. has a 12-month low of $10.35 and a 12-month high of $19.87. The company’s 50 day moving average is $13.26 and its 200 day moving average is $15.35. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -27.85, a PEG ratio of 5.23 and a beta of 1.49.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. On average, equities research analysts predict that Certara, Inc. will post 0.27 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.